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Using fluorescence in situ hybridization (FISH), we previously
showed that the LRIG1 gene had an increased copy number
in 11 of 28 (39%) breast cancer tumours [1]. The LRIG1 gene
(leucine-rich repeats and immunoglobulin-like domains 1) at
chromosome 3p14 is a proposed tumour suppressor gene
that negatively regulates various receptor tyrosine kinases,
including the breast cancer proto-oncogene product ERBB2
[2,3].
Recently, however, Miller and colleagues [4] showed that 10
of 13 (76%) ERBB2+ tumours had decreased LRIG1 protein
levels compared to normal breast tissue. As their data
showed down-regulation at the protein level whereas our data
showed an increased copy number at the genomic level, we
analysed 45 additional breast tumours by FISH as previously
described [1]. Thus, out of 73 tumours analysed to date, 25
(34%) did indeed have increased LRIG1 copy number. To
further analyse the relationship between LRIG1 and ERBB2
at the genomic level, we evaluated the ERBB2 gene copy
numbers in 18 tumours with increased LRIG1 copy number
using FISH analysis according to standard procedures. Inter-
estingly, 16 (89%) out of the 18 tumours displayed increased
copy number of ERBB2  (Figure 1). This suggests that the
majority of breast cancer tumours with increased copy
number of ERBB2 simultaneously had increased LRIG1 copy
number (our data) and decreased LRIG1 protein levels [4].
We draw the following major conclusions from these results.
First, as previously shown, a significant proportion of breast
tumours have an increased LRIG1 gene dosage. Second,
there is a correlation between increased gene copy numbers
of  ERBB2  and  LRIG1. Third, based on the Miller protein
data, most of the tumours with increased LRIG1 gene
dosage express reduced levels of the LRIG1 protein. This
indicates a negative selection against LRIG1 protein
expression, supporting the notion that LRIG1 is a tumour
suppressor in breast cancer. Although the mechanism behind
the down-regulation of LRIG1 protein in breast cancer is not
known, it has been reported that increased gene copy
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FISH = fluorescence in situ hybridization.
Figure 1
Increased copy number of LRIG1 and ERBB2 in human breast cancer
in the same patient. Interphase nuclei from a breast cancer tumour
were analysed by FISH. (a) A specific LRIG1 probe (red) showed
increased LRIG1 copy number (five copies) whereas a specific
centromere probe (CEP3) (green) showed normal chromosome 3
copy number (two copies). (b) A specific ERBB2 probe (red) showed
amplification of the ERBB2 gene whereas a specific centromere probe
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numbers in some cases are associated with decreased
mRNA expression [5]. In any case, the high frequency (34%)
of tumours with increased LRIG1 gene copy number implies
a positive selection for tumour cells with this genomic
alteration. It remains, however, to be elucidated whether the
molecular driver behind the selective advantage associated
with this alteration is LRIG1 down-regulation per se. Other
possibilities include activation of nearby proto-oncogenes or
the generation of novel oncogenic fusion genes.
In summary, the co-incidental increase in copy number of
ERBB2 and  LRIG1 in breast cancer is a novel finding,
pointing at a functional co-operation between these genetic
events, where the biological and clinical importance need to
be clarified further.
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